An alternative to Eliquis (apixaban) for patients with renal disease is warfarin, but it requires careful monitoring of INR levels due to increased risks of bleeding and requires dietary considerations.
Warfarin is a vitamin K antagonist that is commonly used as an alternative anticoagulant for patients with renal impairment when newer oral anticoagulants like Eliquis are contraindicated or need to be avoided.
Regular monitoring of the International Normalized Ratio (INR) is crucial in patients on warfarin, especially in those with renal disease, to avoid over-anticoagulation and associated bleeding risks.
Patients on warfarin need to maintain a consistent intake of vitamin K through their diet, as fluctuations can affect INR levels and the effectiveness of the drug.
Warfarin interacts with many other medications and foods, and these interactions can affect its anticoagulant effect, necessitating adjustments in dosage.
The initiation of warfarin therapy in patients with renal disease should be approached with caution, and dose adjustments may be necessary based on INR results and renal function.